CA2997343A1 - Pharmaceutical formulations for the oral delivery of peptide drugs - Google Patents

Pharmaceutical formulations for the oral delivery of peptide drugs Download PDF

Info

Publication number
CA2997343A1
CA2997343A1 CA2997343A CA2997343A CA2997343A1 CA 2997343 A1 CA2997343 A1 CA 2997343A1 CA 2997343 A CA2997343 A CA 2997343A CA 2997343 A CA2997343 A CA 2997343A CA 2997343 A1 CA2997343 A1 CA 2997343A1
Authority
CA
Canada
Prior art keywords
complex
salt
sodium
iron
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2997343A
Other languages
English (en)
French (fr)
Inventor
Florian Foger
Martin Werle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cyprumed GmbH
Original Assignee
Cyprumed GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyprumed GmbH filed Critical Cyprumed GmbH
Publication of CA2997343A1 publication Critical patent/CA2997343A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CA2997343A 2015-10-07 2016-10-07 Pharmaceutical formulations for the oral delivery of peptide drugs Abandoned CA2997343A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15188838.5 2015-10-07
EP15188838 2015-10-07
PCT/EP2016/074110 WO2017060500A1 (en) 2015-10-07 2016-10-07 Pharmaceutical formulations for the oral delivery of peptide drugs

Publications (1)

Publication Number Publication Date
CA2997343A1 true CA2997343A1 (en) 2017-04-13

Family

ID=54292636

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2997343A Abandoned CA2997343A1 (en) 2015-10-07 2016-10-07 Pharmaceutical formulations for the oral delivery of peptide drugs

Country Status (8)

Country Link
US (1) US10905744B2 (https=)
EP (1) EP3359181A1 (https=)
JP (1) JP2018529749A (https=)
CN (1) CN108135962A (https=)
AU (1) AU2016335287A1 (https=)
CA (1) CA2997343A1 (https=)
IL (1) IL258464A (https=)
WO (1) WO2017060500A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2651398T1 (en) 2010-12-16 2018-04-30 Novo Nordisk A/S SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS
PL2696687T3 (pl) 2011-04-12 2017-06-30 Novo Nordisk A/S Pochodne podwójnie acylowanej GLP-1
HRP20181447T1 (hr) 2012-03-22 2018-11-02 Novo Nordisk A/S Pripravci glp-1 peptida i njihova priprava
PT2827845T (pt) 2012-03-22 2019-03-29 Novo Nordisk As Composições compreendendo um agente de entrega e sua preparação
JP6517690B2 (ja) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
KR102272671B1 (ko) 2013-05-02 2021-07-06 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
KR20180067573A (ko) * 2015-10-09 2018-06-20 라디우스 헬쓰, 인코포레이티드 PTHrP 유사체의 제형, 이의 경피 패취, 및 이의 용도
US10568937B2 (en) 2016-04-18 2020-02-25 Radius Health, Inc. Formulations of abaloparatide, transdermal patches thereof, and uses thereof
CN109381695A (zh) * 2017-08-09 2019-02-26 武汉武药科技有限公司 一种门冬氨酸帕瑞肽注射液及其制备方法和用途
TWI751379B (zh) * 2017-09-21 2022-01-01 奧孟亞股份有限公司 用於遞送胜肽之藥物組合物
JP6898518B2 (ja) * 2018-02-02 2021-07-07 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物
WO2019193204A1 (en) * 2018-04-06 2019-10-10 Cyprumed Gmbh Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
CA3102509A1 (en) * 2018-06-10 2019-12-19 Zim Laboratories Limited Oral mucosal delivery systems comprising monophasic concentrate of teriparatide
GB201813678D0 (en) * 2018-08-22 2018-10-03 Keybioscience Ag Acylated calcitonin mimetics
CA3112060A1 (en) * 2018-10-12 2020-04-16 Advanced Accelerator Applications International Sa Pharmaceutical composition comprising a radiolabeled gprp antagonist and a surfactant
WO2020180534A1 (en) 2019-03-01 2020-09-10 President And Fellows Of Harvard College Methods and compositions for protein delivery
KR20210137373A (ko) * 2019-03-08 2021-11-17 안야 바이오팜 인코포레이티드 부갑상샘 호르몬 유사체의 경구 제제 및 치료
CN111714643A (zh) * 2019-03-22 2020-09-29 约翰霍普金斯大学 一种单宁酸/Fe3+纳米颗粒体系、药物递送方法
GB201906917D0 (en) * 2019-05-16 2019-07-03 Intract Pharma Ltd Novel compositions
CN112057619A (zh) * 2019-06-10 2020-12-11 苏州兰鼎生物制药有限公司 一种具有降血糖作用的药物组合物
TW202143997A (zh) * 2020-03-18 2021-12-01 大陸商四川海思科製藥有限公司 口服藥物組合物
US20210315930A1 (en) * 2020-04-14 2021-10-14 David A. Cuddeback Nutraceutical composition for multimodal prophylaxis against and treatment of viral and bacterial infection and inflammation
CN114306917A (zh) * 2021-01-12 2022-04-12 广州新济药业科技有限公司 可溶性微针贴片及其制备方法
FR3120189B1 (fr) 2021-03-01 2024-11-29 Farid Bennis Composition pharmaceutique pour une administration par voie orale d’un agoniste du récepteur du GLP-1
CN113117050B (zh) * 2021-05-06 2022-04-26 合肥天汇孵化科技有限公司 多肽组合物及其用途
AU2022386166A1 (en) 2021-11-10 2024-06-20 I2O Therapeutics, Inc. Ionic liquid compositions
WO2024043867A1 (en) * 2022-08-20 2024-02-29 Sinapu Llc C60 histidine carnosine fumarates and use
CN115321657B (zh) * 2022-08-31 2023-10-03 四川农业大学 一种疏水壳聚糖-聚合氯化铝Hmcs-PAC复合絮凝剂及其制备与应用
WO2024077409A1 (en) * 2022-10-09 2024-04-18 Guangzhou Dazhou Biomedicine Ltd. Oral delivery of therapeutic agents
WO2025046590A1 (en) * 2023-08-30 2025-03-06 Entera Bio Ltd. Formulations for oral administration of active agents
US12377156B2 (en) 2023-10-24 2025-08-05 Neuvian Ip Holdings, Llc Compositions and methods for treatment of wounds and inflammatory skin conditions
US20250235509A1 (en) * 2024-01-23 2025-07-24 Men Hwei Tsai Formulation and Method of Preparing Glucagon-like Peptide-1 (GLP-1) for Oral Administration
WO2025188317A1 (en) * 2024-03-08 2025-09-12 Neuvian Skincare Llc Compositions and methods for hair treatment
US12409204B1 (en) 2024-03-08 2025-09-09 Neuvian Ip Holdings, Llc Compositions and methods for hair treatment
WO2025251740A1 (en) * 2024-06-03 2025-12-11 Shenzhen Oralead Pharma Co., LTD. Oral polypeptide composition

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
US5661130A (en) 1993-06-24 1997-08-26 The Uab Research Foundation Absorption enhancers for drug administration
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
CN1228708A (zh) 1996-09-04 1999-09-15 有限会社多特 经口给药用含肽药物组合物
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
JP2002506792A (ja) 1998-02-27 2002-03-05 ノボ ノルディスク アクティーゼルスカブ Ｎ末端修飾ｇｌｐ−１誘導体
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
EP1061946B1 (en) 1998-02-27 2004-04-28 Novo Nordisk A/S Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
WO1999043706A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Derivatives of glp-1 analogs
ES2235854T3 (es) 1999-04-05 2005-07-16 Emisphere Technologies, Inc. Sales disodicas, monohidratos y solvatos etanolicos para aportar agentes activos.
ATE267582T1 (de) 2000-01-20 2004-06-15 Basilea Pharmaceutica Ag Nasal verabreichbare cyclische antimykotische peptidzusammensetzungen
US6248360B1 (en) 2000-06-21 2001-06-19 International Health Management Associates, Inc. Complexes to improve oral absorption of poorly absorbable antibiotics
US20030017195A1 (en) 2001-07-20 2003-01-23 Samir Mitragotri Method for oral drug delivery
KR20040058324A (ko) 2001-11-26 2004-07-03 다이이찌 산토리 파마 가부시키가이샤 경비흡수용 의약 조성물
WO2004024225A1 (en) 2002-09-16 2004-03-25 Zicam, Llc. System and method for delivering a composition to the nasal membrane
BR122019021416A2 (https=) 2003-09-19 2019-12-21
ATE461217T1 (de) 2003-12-18 2010-04-15 Novo Nordisk As Glp-1-verbindungen
EP1696962A2 (en) 2003-12-18 2006-09-06 Novo Nordisk A/S Novel glp-1 analogues linked to albumin-like agents
EA018643B1 (ru) 2004-02-23 2013-09-30 Цайтэн Чжан Раствор металлсодержащего хелатного полимера и его применение (варианты)
CA2572770A1 (en) 2004-07-08 2006-01-19 Novo-Nordisk A/S Polypeptide protracting tags comprising a tetrazole moiety
JP2006028031A (ja) * 2004-07-12 2006-02-02 Ltt Bio-Pharma Co Ltd 経粘膜吸収用薬物封入ナノ粒子
RU2527893C2 (ru) 2004-07-19 2014-09-10 Биокон Лимитед Инсулин-олигомерные конъюгаты, их препараты и применения
EP1781257B1 (en) 2004-08-13 2018-12-19 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
JP5066448B2 (ja) 2004-09-03 2012-11-07 協和発酵バイオ株式会社 口内炎の予防または治療のための組成物および方法
WO2006037810A2 (en) 2004-10-07 2006-04-13 Novo Nordisk A/S Protracted glp-1 compounds
US8030273B2 (en) 2004-10-07 2011-10-04 Novo Nordisk A/S Protracted exendin-4 compounds
US8603972B2 (en) 2005-03-18 2013-12-10 Novo Nordisk A/S Extended GLP-1 compounds
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
WO2007025332A1 (en) 2005-08-29 2007-03-08 Dia-B Tech Limited A peptide and zinc ion composition for treating diabetes and enhancing immune function
WO2007029238A2 (en) 2005-09-06 2007-03-15 Oramed Pharmaceuticals, Inc. Methods and compositions for oral administration of proteins
WO2007041481A1 (en) 2005-09-29 2007-04-12 Biodel, Inc. Rapid acting and prolonged acting insulin preparations
CN101309668A (zh) 2005-11-30 2008-11-19 健乐克斯医药公司 经口吸收的药物制剂和用药方法
WO2008023050A1 (en) 2006-08-25 2008-02-28 Novo Nordisk A/S Acylated exendin-4 compounds
EP2190872B1 (en) 2007-09-05 2018-03-14 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
WO2009030771A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
US20100292133A1 (en) 2007-09-05 2010-11-18 Novo Nordisk A/S Truncated glp-1 derivaties and their therapeutical use
PE20110543A1 (es) 2008-08-15 2011-08-04 Ironwood Pharmaceuticals Inc Formulacion solida oral que comprende linaclotida, cation de calcio y leucina
RU2548807C2 (ru) 2009-05-20 2015-04-20 Торэй Индастриз, Инк. Пептиды, проникающие в клетку
CA2770077A1 (en) 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
MX2012001691A (es) * 2009-08-12 2012-02-29 Forest Lab Holdings Ltd Composiciones de linaclotida que se desintegran oralmente.
JP6016234B2 (ja) 2009-09-30 2016-10-26 ティオマトリックス・フォルシュンクス・ウント・べラートゥンクス・ゲーエムベーハー ビタミンｂ部分構造を持つ粘膜付着性ポリマー
US20110311621A1 (en) 2010-03-16 2011-12-22 Paul Salama Pharmaceutical compositions and methods of delvery
CN102970864A (zh) 2010-04-21 2013-03-13 那挪玛加医药有限公司 纳米颗粒药物组合物
CN103347532A (zh) 2011-02-04 2013-10-09 爱奇司治疗公司 口服可生物利用肽药物组合物及其方法
EP2696847A1 (en) 2011-04-14 2014-02-19 Novo Nordisk A/S Fatty acid acylated amino acids for oral peptide delivery
EP2717858B1 (en) 2011-06-10 2018-08-08 Aquestive Therapeutics, Inc. Combination peptide-nanoparticles and delivery systems incorporating same
US20130004590A1 (en) 2011-06-28 2013-01-03 Lin Connie B Zinc oxide/acid containing compositions and methods for treating and/or preventing enzymatic irritation
HRP20181447T1 (hr) 2012-03-22 2018-11-02 Novo Nordisk A/S Pripravci glp-1 peptida i njihova priprava
IN2014MN02304A (https=) 2012-05-03 2015-08-07 Zealand Pharma As
US20150174076A1 (en) 2012-06-14 2015-06-25 Entrega, Inc. Mucoadhesive devices for delivery of active agents
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
ES2630106T3 (es) 2014-10-07 2017-08-18 Cyprumed Gmbh Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos
WO2018065634A1 (en) 2016-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical compositions for the nasal delivery of peptide or protein drugs

Also Published As

Publication number Publication date
US20180280481A1 (en) 2018-10-04
US10905744B2 (en) 2021-02-02
EP3359181A1 (en) 2018-08-15
CN108135962A (zh) 2018-06-08
IL258464A (en) 2018-05-31
JP2018529749A (ja) 2018-10-11
WO2017060500A1 (en) 2017-04-13
AU2016335287A1 (en) 2018-04-12

Similar Documents

Publication Publication Date Title
US10905744B2 (en) Pharmaceutical formulations for the oral delivery of peptide drugs
EP3204045B1 (en) Pharmaceutical formulations for the oral delivery of peptide or protein drugs
JP2024054333A (ja) 治療用ペプチド及び治療用タンパク質の経粘膜送達のための薬学的組成物
WO2018065634A1 (en) Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
ES2541309T3 (es) Productos farmacéuticos peptídicos orales de acción rápida
JP2018529749A5 (https=)
WO2022049310A1 (en) Improved pharmaceutical formulations of glp-1 receptor agonists
EP4200319B1 (en) Annexin a1 n-terminal peptide formulations and methods
EP4262745B1 (en) Pharmaceutical composition of glp-1/glp-2 dual agonists
AU2010323117B2 (en) Mucosal delivery compositions comprising a peptide complexed with a crown comppound and/or a counter ion
WO2025112258A1 (zh) 一种实现多肽口服吸收的组合物
CN119486752A (zh) 包含肽或蛋白和酰化氨基酸的组合物
RU2819934C1 (ru) Жидкие составы аналогов глюкагона
HK40095698B (en) Pharmaceutical composition of glp-1/glp-2 dual agonists
HK40095698A (en) Pharmaceutical composition of glp-1/glp-2 dual agonists

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220407